Epicardial fat, cardiovascular risk factors and calcifications in patients with chronic kidney disease.
Framingham risk score
atherosclerotic cardiovascular disease risk score
chronic kidney disease
epicardial adipose tissue
vascular calcification
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
26
09
2018
accepted:
19
02
2019
entrez:
9
9
2020
pubmed:
8
4
2019
medline:
8
4
2019
Statut:
epublish
Résumé
Epicardial adipose tissue (EAT) exerts cardiopathogenic effects, but the independent association between EAT and cardiovascular (CV) calcification in patients with chronic kidney disease (CKD) remains controversial. We therefore assessed the association between EAT, CV risk factors and CV calcifications. 257 patients with CKD Stage 3 and/or overt proteinuria underwent quantification of EAT, coronary artery calcification and aortic valve calcification by computed tomography. Framingham and American College of Cardiology and American Heart Association (ACC-AHA) 10-year CV event risk scores were calculated for each patient. Using multivariable regression analysis, higher EAT was significantly associated with the majority of investigated risk factors {higher age: odds ratio [OR] 1.05/year [95% confidence interval (CI) 1.02-1.08]; male sex: OR 4.03 [95% CI 2.22-7.31]; higher BMI: OR 1.28/kg/m The increase of EAT can be explained by individual CV risk factors and kidney function and correlates with 10-year risk for CV event scores, suggesting that EAT is a modifiable risk factor in patients with CKD. Although EAT correlates with CV calcifications, these relations depend on CV risk factors.
Sections du résumé
BACKGROUND
BACKGROUND
Epicardial adipose tissue (EAT) exerts cardiopathogenic effects, but the independent association between EAT and cardiovascular (CV) calcification in patients with chronic kidney disease (CKD) remains controversial. We therefore assessed the association between EAT, CV risk factors and CV calcifications.
METHODS
METHODS
257 patients with CKD Stage 3 and/or overt proteinuria underwent quantification of EAT, coronary artery calcification and aortic valve calcification by computed tomography. Framingham and American College of Cardiology and American Heart Association (ACC-AHA) 10-year CV event risk scores were calculated for each patient.
RESULTS
RESULTS
Using multivariable regression analysis, higher EAT was significantly associated with the majority of investigated risk factors {higher age: odds ratio [OR] 1.05/year [95% confidence interval (CI) 1.02-1.08]; male sex: OR 4.03 [95% CI 2.22-7.31]; higher BMI: OR 1.28/kg/m
CONCLUSIONS
CONCLUSIONS
The increase of EAT can be explained by individual CV risk factors and kidney function and correlates with 10-year risk for CV event scores, suggesting that EAT is a modifiable risk factor in patients with CKD. Although EAT correlates with CV calcifications, these relations depend on CV risk factors.
Identifiants
pubmed: 32905245
doi: 10.1093/ckj/sfz030
pii: sfz030
pmc: PMC7467583
doi:
Types de publication
Journal Article
Langues
eng
Pagination
571-579Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Nefrologia. 2017 May - Jun;37(3):293-300
pubmed: 28495396
Scand Cardiovasc J. 2014 Oct;48(5):317-22
pubmed: 25022871
J Intern Med. 2015 Jul;278(1):77-87
pubmed: 25556720
J Diabetes Res. 2015;2015:924539
pubmed: 26064992
J Nephrol. 2016 Apr;29(2):241-250
pubmed: 26253562
J Am Soc Nephrol. 2017 Jun;28(6):1867-1876
pubmed: 28154199
Nephrol Dial Transplant. 2012 Apr;27(4):1454-60
pubmed: 21862458
Am J Cardiol. 2011 Dec 1;108(11):1680-5
pubmed: 21880291
Kidney Int Suppl. 2009 Aug;(113):S1-130
pubmed: 19644521
Cardiovasc Diabetol. 2006 Jan 13;5:1
pubmed: 16412224
PLoS One. 2014 Jul 22;9(7):e103381
pubmed: 25051047
Ann Intern Med. 2013 Apr 16;158(8):596-603
pubmed: 23588748
Circulation. 2003 Nov 18;108(20):2460-6
pubmed: 14581396
Eur Heart J. 2009 Apr;30(7):850-6
pubmed: 19136488
Eur Heart J Cardiovasc Imaging. 2018 May 1;19(5):490-497
pubmed: 29236951
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Nephrol Dial Transplant. 2015 Mar;30(3):441-51
pubmed: 25271006
BMC Nephrol. 2013 Jan 26;14:26
pubmed: 23351146
Cardiovasc Diabetol. 2019 Jan 10;18(1):3
pubmed: 30630489
Clin J Am Soc Nephrol. 2011 Aug;6(8):1920-5
pubmed: 21757644
JACC Cardiovasc Imaging. 2012 Jun;5(6):619-25
pubmed: 22698532
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
N Engl J Med. 2008 Mar 27;358(13):1336-45
pubmed: 18367736
Am J Cardiol. 2012 Dec 15;110(12):1735-41
pubmed: 22980963
Nephrol Dial Transplant. 2010 Aug;25(8):2695-701
pubmed: 20190243
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
Ren Fail. 2011;33(8):770-5
pubmed: 21770856
Am J Clin Nutr. 2009 Sep;90(3):499-504
pubmed: 19571212
Obesity (Silver Spring). 2017 Feb;25(2):311-316
pubmed: 28124506
Atherosclerosis. 2016 Dec;255:37-42
pubmed: 27816807
J Comput Assist Tomogr. 2014 Sep-Oct;38(5):768-72
pubmed: 24879458
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Circ J. 2016;80(1):196-201
pubmed: 26497330
Circulation. 2008 Feb 5;117(5):605-13
pubmed: 18212276
PLoS One. 2012;7(9):e45815
pubmed: 23029258
J Clin Endocrinol Metab. 2003 Nov;88(11):5163-8
pubmed: 14602744
Curr Opin Nephrol Hypertens. 2015 Nov;24(6):517-24
pubmed: 26335554
JAMA Cardiol. 2017 Jun 1;2(6):635-643
pubmed: 28329057
J Am Soc Nephrol. 2013 Nov;24(11):1727-36
pubmed: 24115475
J Am Soc Nephrol. 2015 May;26(5):1173-80
pubmed: 25395432
Int J Obes Relat Metab Disord. 1994 Apr;18(4):207-2
pubmed: 8044194
Obes Res. 2003 Feb;11(2):304-10
pubmed: 12582228
Nephrol Dial Transplant. 1999 Oct;14(10):2427-32
pubmed: 10528668
J Am Coll Cardiol. 2013 May 14;61(19):1956-61
pubmed: 23500254
Europace. 2017 May 1;19(5):747-752
pubmed: 28087595
Eur Heart J Cardiovasc Imaging. 2015 Nov;16(11):1264-9
pubmed: 25908795
Am J Cardiol. 2015 May 1;115(9):1281-6
pubmed: 25791240
Nephrol Dial Transplant. 2000 Jul;15(7):953-60
pubmed: 10862630